PubRank

Robert W Buchanan

Author PubWeight™ 103.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004 7.58
2 Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 3.54
3 Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008 3.13
4 The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2009 2.61
5 Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry 2006 1.86
6 Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 2008 1.81
7 Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008 1.78
8 The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007 1.73
9 Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res 2005 1.69
10 Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 1.68
11 Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res 2004 1.65
12 Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry 2002 1.62
13 Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 2008 1.52
14 Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2009 1.41
15 Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 2006 1.39
16 Galantamine-induced QTc prolongation. J Clin Psychiatry 2006 1.38
17 Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res 2012 1.37
18 Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry 2002 1.36
19 The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004 1.35
20 Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 2005 1.34
21 Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011 1.33
22 Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res 2004 1.33
23 Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2006 1.30
24 No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005 1.29
25 Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009 1.28
26 Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2007 1.27
27 Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry 2011 1.26
28 Factor structure of the Brief Negative Symptom Scale. Schizophr Res 2012 1.23
29 Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003 1.18
30 Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2011 1.17
31 Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 2013 1.16
32 An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002 1.16
33 Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res 2006 1.12
34 Working memory for visual features and conjunctions in schizophrenia. J Abnorm Psychol 2003 1.11
35 Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry 2004 1.09
36 Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res 2013 1.08
37 Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011 1.08
38 Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2011 1.08
39 The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials. Schizophr Res 2007 1.07
40 A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2012 1.04
41 Lessons to take home from CATIE. Psychiatr Serv 2008 1.04
42 Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport 2004 1.04
43 Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003 1.04
44 Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry 2007 1.02
45 White matter alterations in deficit schizophrenia. Neuropsychopharmacology 2008 1.02
46 Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology 2007 0.99
47 The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004 0.98
48 Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2011 0.97
49 The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry 2003 0.96
50 A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 2009 0.92
51 The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002 0.92
52 Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013 0.92
53 Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophr Res 2011 0.91
54 Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res 2005 0.89
55 Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 2011 0.89
56 Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry 2011 0.88
57 Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. Schizophr Res 2010 0.87
58 Advancing drug discovery for schizophrenia. Ann N Y Acad Sci 2011 0.86
59 Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res 2012 0.86
60 Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003 0.85
61 Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull 2002 0.85
62 Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res 2008 0.85
63 Evidence-based treatment for schizophrenia. Psychiatr Clin North Am 2003 0.85
64 Evidence-based early interventions for individuals at clinical high risk for psychosis: a review of treatment components. J Nerv Ment Dis 2015 0.85
65 Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res 2013 0.84
66 Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res 2008 0.84
67 Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry 2013 0.83
68 Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 2011 0.83
69 Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005 0.83
70 Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010 0.83
71 Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry 2003 0.82
72 The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol 2009 0.81
73 Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. Psychopharmacology (Berl) 2014 0.81
74 Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses 2011 0.81
75 Important steps in the development of cognitive-enhancing drugs in schizophrenia. Am J Psychiatry 2006 0.80
76 Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. J Clin Psychopharmacol 2015 0.80
77 Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct 2006 0.79
78 The family pictures test as a measure of impaired feature binding in schizophrenia. J Clin Exp Neuropsychol 2004 0.79
79 Commentary on the Soteria project: misguided therapeutics. Schizophr Bull 2002 0.78
80 Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry 2013 0.78
81 The potential of nicotinic enhancement of cognitive remediation training in schizophrenia. Neuropharmacology 2012 0.78
82 Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis 2014 0.76
83 Celebrating the work of William T. Carpenter Jr. Schizophr Bull 2014 0.75
84 Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009. PLoS One 2013 0.75
85 Research and services partnerships: the practice research network: a successful collaboration in Maryland. Psychiatr Serv 2013 0.75
86 Weight and blood pressure change during clozapine treatment. Clin Neuropharmacol 2002 0.75
87 Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol 2013 0.75
88 Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia. Schizophr Res 2013 0.75